Abstract:The incidence of non-steroidal anti-inflammatory drug-related ulcer complications remains high despite the availability of potent anti-ulcer drugs and selective cyclo-oxygenase-2 inhibitors. Non-steroidal anti-inflammatory drug-related ulcer complications can be minimized by prospective assessment of patients' baseline risk, rational choice and use of non-steroidal anti-inflammatory drugs, and selective use of co-therapy strategies with gastroprotectives. Current recommendations regarding strategies using anti-ulcer drugs and cyclo-oxygenase-2 inhibitors for prevention of clinical non-steroidal anti-inflammatory drug upper gastrointestinal events are largely derived from studies using surrogates such as endoscopic ulcers, erosions, and symptoms in low- to average-risk patients. Conclusions based on surrogate and potentially manipulatable end-points are increasingly suspect with regard to applicability to clinical situations. This article reviews the risks associated with non-steroidal anti-inflammatory drugs including aspirin and includes the effect of the patients' baseline risk, and the confounding effects of Helicobacter pylori infection. In addition, uncertainties regarding the clinical efficacy of anti-ulcer drugs and cyclo-oxygenase-2 inhibitors against non-steroidal anti-inflammatory drug-related ulcer complications are put into perspective. We propose management strategies based on the risk category: low risk (absence of risk factors) (least ulcerogenic non-steroidal anti-inflammatory drug at lowest effective dose), moderate risk (one to two risk factors) (as above, plus an antisecretory agent or misoprostol or a cyclo-oxygenase-2 inhibitor), high risk (multiple risk factors or patients using concomitant low-dose aspirin, steroids, or anticoagulants) (cyclo-oxygenase-2 inhibitor alone with steroids, plus misoprostol with warfarin, or plus a proton pump inhibitors or misoprostol with aspirin), and very high risk (history of ulcer complications) (avoid all non-steroidal anti-inflammatory drugs, if possible or a cyclo-oxygenase-2 plus a proton pump inhibitors and/or misoprostol). The presence of H. pylori infection increases the risk of upper gastrointestinal complications in non-steroidal anti-inflammatory drug users by two- to fourfold suggesting that all patients requiring regular non-steroidal anti-inflammatory drug therapy be tested for H. pylori.

Duodenal and Gastric Ulcer Prevention with Misoprostol in Arthritis Patients Taking NSAIDs

Effects of nonsteroidal anti-inflammatory drugs and misoprostol on gastroduodenal epithelial proliferation in arthritis

Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY.

Risk of Upper Gastrointestinal Ulcers in Patients With Osteoarthritis Receiving Single-Tablet Ibuprofen/Famotidine Versus Ibuprofen Alone: Pooled Efficacy and Safety Analyses of Two Randomized, Double-Blind, Comparison Trials

114 Combination of a Cyclooxygenase (COX)-2 Selective NSAID and a Proton Pump Inhibitor for Prevention of Gastroduodenal Ulcers in Very High Risk Patients: A One-Year, Double-Blind, Randomized Trial

The David Y. Graham Lecture: Use of Nonsteroidal Antiinflammatory Drugs in a COX-2 Restricted Environment

Upper gastrointestinal disorders induced by non-steroidal anti-inflammatory drugs

For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor?

Comparative antiplatelet activity of COX1 NSAIDS versus aspirin, encompassing regimen simplification and gastroprotection: a call for a controlled study

Misoprostol Heals Small Bowel Ulcers in Aspirin Users With Small Bowel Bleeding.

Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment

Primer: Managing NSAID-induced Ulcer Complications—balancing Gastrointestinal and Cardiovascular Risks

Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.

Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors

Drugs Effective for Nonsteroidal Anti-inflammatory Drugs or Aspirin-induced Small Bowel Injuries: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Efficacy and Safety of Rectal Nonsteroidal Anti-Inflammatory Drugs for Prophylaxis Against Post-Ercp Pancreatitis: A Systematic Review and Meta-Analysis

Nonsteroidal Anti‐Inflammatory Drug‐Gastropathy and Enteropathy

Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial

S2294 Evaluating Prophylactic Gastric Acid Suppression and Risk Factors for Gastrointestinal Adverse Effects in Chronic NSAID Users: A Retrospective Analysis

Systematic Review with Network Meta-Analysis: Comparative Effectiveness and Safety of Strategies for Preventing NSAID-associated Gastrointestinal Toxicity

Prospective Randomized Trial of H-Pylori Eradication Versus Maintenance Omeprazole to Prevent Recurrent Upper Gastrointestinal Hemorrhage in High-Risk Aspirin and Non-Aspirin Nsaid Users.